Episode Summary In this episode of the Verisian Community Podcast, Richardus Vonk discusses the transformative role of AI in clinical trials. He explores how AI is reshaping trial planning and execution, improving early disease detection like cancer, and the challenges it still faces in drug development. Richardus also highlights the benefits of automation in freeing up time for deeper scientific exploration and elaborates on the tactical versus strategic use of AI and GenAI. The conversation touches on the rise of open-source tools, balancing data sharing with patient privacy, while offering a vision for the future of clinical trials over the next decade. Biography Richardus Vonk Richardus Vonk, Biostatistics Leader, Entrepreneur, Advisor Richardus is a distinguished leader in quantitative decision-making within pharmaceutical clinical development, with over 30 years of extensive experience. He is a passionate advocate of leveraging data to enhance the success of drug development programs, emphasizing how actionable insights provide a competitive edge. Previously serving as the VP and Head of Oncology Data Analytics and Statistical Sciences at Bayer AG, Richardus now advises a diverse range of organizations in the life sciences and pharmaceutical sectors, including software companies and start-ups. He focuses on unlocking the potential of clinical and real-world data as well as advanced data-science technologies to innovate and transform the clinical trial landscape. Resources Learn more about us: https://www.verisian.com/ Join the Verisian Community: https://www.verisian.com/community Follow us on LinkedIn: https://www.linkedin.com/company/verisian/

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related